{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:50:12Z","timestamp":1785552612911,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K06771"],"award-info":[{"award-number":["18K06771"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.biopha.2022.112619","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T04:28:04Z","timestamp":1641443284000},"page":"112619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Comparison of cisplatin-induced nephrotoxicity between single-dose and split-dose administration to rats"],"prefix":"10.1016","volume":"147","author":[{"given":"Keizo","family":"Fukushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Futatsugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saya","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Sugioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112619_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2022.112619_bib2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.12998\/wjcc.v7.i5.600","article-title":"Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: a systematic review and meta-analysis","volume":"7","author":"Li","year":"2019","journal-title":"World J. Clin. Cases"},{"issue":"3","key":"10.1016\/j.biopha.2022.112619_bib3","first-page":"559","article-title":"Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review)","volume":"11","author":"Boulikas","year":"2004","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2022.112619_bib4","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/acs.chemrestox.9b00204","article-title":"Advances in toxicological research of the anticancer drug cisplatin","volume":"32","author":"Qi","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"11","key":"10.1016\/j.biopha.2022.112619_bib5","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"issue":"6","key":"10.1016\/j.biopha.2022.112619_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","article-title":"European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care","volume":"61","author":"Launay-Vacher","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112619_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920923430","article-title":"Cisplatin-induced renal toxicity in elderly people","volume":"12","author":"Duan","year":"2020","journal-title":"Ther. Adv. Med Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2022.112619_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-019-0609-6","article-title":"Treatment approaches for cisplatin-ineligible patients with invasive bladder cancer","volume":"20","author":"Einstein","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2022.112619_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF00253069","article-title":"High-dose cis-platinum combination chemotherapy in advanced nonseminomatous malignant germ cell tumours with emphasis on nephrotoxicity","volume":"18","author":"Hall","year":"1986","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2022.112619_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.athoracsur.2006.02.061","article-title":"Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer","volume":"82","author":"Daly","year":"2006","journal-title":"Ann. Thorac. Surg."},{"issue":"9","key":"10.1016\/j.biopha.2022.112619_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","article-title":"Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data","volume":"22","author":"Szturz","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.biopha.2022.112619_bib12","first-page":"927","article-title":"Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer","volume":"34","author":"Hirai","year":"2014","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.112619_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/00000421-198812000-00008","article-title":"Etoposide and split-dose cisplatin in bronchogenic carcinoma","volume":"11","author":"Lauer","year":"1988","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.112619_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.12659\/MSM.892730","article-title":"Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience","volume":"21","author":"Mertsoylu","year":"2015","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"10.1016\/j.biopha.2022.112619_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2009.05.018","article-title":"Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer","volume":"68","author":"Funai","year":"2010","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2022.112619_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2019.01.007","article-title":"Comparative effectiveness study of single high-dose cisplatin with fractionated doses cisplatin in first-line therapy for treatment-naive Chinese patients with advanced non-small-cell lung cancer","volume":"43","author":"Li","year":"2019","journal-title":"Curr. Probl. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2022.112619_bib17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1634\/theoncologist.2018-0561","article-title":"Efficacy of split schedule versus conventional schedule neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer","volume":"24","author":"Osterman","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.biopha.2022.112619_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.biopha.2022.112619_bib19","first-page":"4151","article-title":"Management of nephrotoxicity of chemotherapy and targeted agents: 2020","volume":"10","author":"Chiruvella","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2022.112619_bib20","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1248\/bpb.b17-00499","article-title":"Alterations in cisplatin pharmacokinetics and its acute\/sub-chronic kidney injury over multiple cycles of cisplatin treatment in rats","volume":"40","author":"Okada","year":"2017","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.biopha.2022.112619_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2022.112619_bib22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4161\/auto.6309","article-title":"Autophagy delays apoptosis in renal tubular epithelial cells in cisplatin cytotoxicity","volume":"4","author":"Kaushal","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2022.112619_bib23","article-title":"Evaluation of acute and chronic nephrotoxicity in patients received cisplatin-based chemotherapy: Has anything changed over time?","author":"Kamac\u0131","year":"2021","journal-title":"Int. Urol. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2022.112619_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: a review","volume":"334","author":"Yao","year":"2007","journal-title":"Am. J. Med. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2022.112619_bib25","doi-asserted-by":"crossref","first-page":"F1582","DOI":"10.1152\/ajprenal.00385.2019","article-title":"Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells","volume":"317","author":"Fu","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.112619_bib26","doi-asserted-by":"crossref","first-page":"F161","DOI":"10.1152\/ajprenal.00636.2017","article-title":"Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease","volume":"315","author":"Sharp","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2022.112619_bib27","doi-asserted-by":"crossref","unstructured":"C. M\u00e1th\u00e9, A. Boh\u00e1cs, L. Duffek, J. Luk\u00e1csovits, Z.I. Komlosi, K. Szondy, I. Horv\u00e1th, V. M\u00fcller, G. Losonczy, Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients, Eur. Respir. J., (2011) Apr;37(4):888\u2013894. doi: 10.1183\/09031936.00055110. (Epub 2010 Jul 22.PMID: 20650984).","DOI":"10.1183\/09031936.00055110"},{"issue":"3","key":"10.1016\/j.biopha.2022.112619_bib28","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.7314\/APJCP.2015.16.3.1117","article-title":"Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia","volume":"16","author":"Prasaja","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.biopha.2022.112619_bib29","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1096\/fj.201901412R","article-title":"Subcellular trafficking of tubular MDM2 implicates in acute kidney injury to chronic kidney disease transition during multiple low-dose cisplatin exposure","volume":"34","author":"Su","year":"2020","journal-title":"FASEB J."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2022.112619_bib30","first-page":"E2151","article-title":"Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review","volume":"38","author":"Strojan","year":"2016","journal-title":"Head Neck"},{"issue":"9","key":"10.1016\/j.biopha.2022.112619_bib31","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s10495-007-0082-8","article-title":"Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation","volume":"12","author":"Bragado","year":"2007","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.biopha.2022.112619_bib32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1681\/ASN.V125900","article-title":"Role of the increase in p21 in cisplatin-induced acute renal failure in rats","volume":"12","author":"Miyaji","year":"2001","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:38:39Z","timestamp":1760099919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":32,"alternative-id":["S0753332222000075"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112619","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of cisplatin-induced nephrotoxicity between single-dose and split-dose administration to rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112619"}}